Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study. - Motzer, R.J.; Albiges, L.; Treviño Aguirre, S.A.; Kanesvaran, R.; Centkowski, P.; Reimers, M.A.; Sade, J.P.; Pouessel, D.; Biscaldi, E.; Esteban, E.; Arranz Arija, J.Á.; Tykodi, S.S.; et al. (Annals of Oncology, 2026)